Industry Insights

  1. Digitally Transforming Laboratory Operations

    “Digital transformation” is a common buzzword across industries today, but is it more than just jargon?  Faced by shifting consumer demand, rapidly evolving technology and increasing competition, organizations — to a large extent from science-based industries — are realizing that business as usual (or only incremental change to traditional approaches) does not address today’s challenges in a sustainable, long-term way.

  2. Why The Shift From Batch To Continuous For Pharmaceutical Oral Solid Manufacturing Is Now Upon Us

    There has been intense interest and emphasis being given to the continuous OSD manufacturing process as an alternative or addition to the traditional batch manufacturing process. 

  3. How To Rapidly Create Single-Use Biomanufacturing Capacity

    To meet therapy production demands, the industry needs to have the right capacity, in the right locations. Increasingly, single-use technologies are being seen as flexible and cost-effective solutions.

  4. Patient-Centric Drug Design — A Clinical And Academic Perspective

    Most issues in pediatric drug development arise from the fact that drugs are traditionally developed for adults and not children. Dr. Meyers shares the hurdles and  improvements in pediatric drug development.

  5. Solutions To Today’s Biomanufacturing Challenges

    With more complex molecules in development, changing capacity needs, uncertain forecasts and increased competition, the market demands flexibility and innovative approaches to today’s challenges.

  6. Lonza And Atvio Biotech Seek To Advance Personalized Medicine

    Despite their potential to increase the efficiency healthcare, autologous cell therapy treatments present significant challenges to most companies when it comes to development and manufacturing. 

  7. BIO 2016 Survey: Where Is Biopharma Headed?

    15,937 industry leaders, 40% of which were C-level executives, attended the BIO International Convention in San Francisco that ran June 6-9. The MilliporeSigma team used this opportune gathering of the biopharma industry to unveil the findings of a study that it recently sponsored with The Economist Intelligence Unit, titled The Changing Biopharma Risk Equation.

  8. Biosimilar Developers Must Scale Mountains of Data

    The U.S. FDA approved Sandoz’s filgrastim product, Zarxio, a biosimilar of Amgen’s Neupogen. This was a big step for the Agency, and one some feel was long in coming. 

  9. Decision Timeline: Considerations In Selecting An Outsourced Solution

    Making a decision between keeping a project in-house versus outsourcing is not an easy one, especially with so much at stake. It is important to consider what decisions need to be made across the development and manufacturing timeline in order to meet your commercialization goals.

  10. Pharma Seeks Long Tail Of Flexible Manufacturing

    It is no secret that pharma lags behind other industries when it comes to innovation in manufacturing, but the industry does have its eye toward new models of manufacturing.